Skip to content
DataLookout
Menu

FEFACRIGOUNCT05109936

Immediate Prescription of a Hypouricemic Treatment, Febuxostat, Compared to Its Delayed Administration

StatusCompleted
PhasePhase 3
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 3 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Final enrollment: 9 participants, 7% of the 128 planned Show 6 more changesShow less
    • Eligibility criteria expanded, about 27 words
    • Primary endpoints: details revised at 1 of 1 entry
    • Trial completed
    • Primary completion date changed from estimate of Jan 1, 2027 to Aug 10, 2026
    • Site details revised at 6 of 6 sites
    • Study description expanded, about 3 words
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Primary and study completion dates: Aug 1, 2025 to Jan 1, 2027
    • Start date changed from estimate of Jan 1, 2022 to Aug 2, 2023
    • Study sites: 0 to 6
    v2
  3. Study First Submitted
  • Notable: the plan changed

Endpoints

Primary

To compare the number of days with gout at 42 days +/- 3 days (W6) in patients with an early administration of febuxostat from the acute attack compared to patients with a delayed administration of febuxostat by 6 weeks after the acute attack.
Timeframe: 6 weeks

Secondary (3)

To compare, in patients with early administration of febuxostat compared to patients with delayed administration the function of the patient during the study (until 26 weeks)
To compare, in patients with early administration of febuxostat compared to patients with delayed administration the intensity of pain during the study (until 26 weeks)
To compare, in patients with early administration of febuxostat compared to patients with delayed administration the tolerance of treatment during the study (until 26 weeks)

Arms and interventions

Experimental armExperimental

Immediate prescription (at randomization) of ADENURIC 80 mg / day (febuxostat), urate-lowering treatment, for a period of 2 x 6 weeks.

Standard care armNo intervention

Prescription deferred to 6 weeks (42 days +/- 3 days) of ADENURIC 80 mg / day (febuxostat): hypouricemic treatment, for a period of 6 weeks.

Drugs: Adenuric

Sites

6 sites in 1 country